New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.

Topics covered include:

Available agents for second-line treatment of PBC
An overview of clinical trial data supporting second-line agents:
Obeticholic acid (OCA)
Bezafibrate
Elafibranor
Seladelpar

This episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/48MEc3r

Presenters:

Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California

Aparna Goel, MD
Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California

Aliya F. Gulamhusein, MD, MPH, FRCPC
Professorship in PSC Research
Clinician Investigator, Toronto General Hospital
Assistant Professor, University of Toronto
Division of Gastroenterology and Hepatology
University Health Network
Toronto, Canada

Get access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.